Zentalis Pharmaceuticals, Inc. cotiza a 2.52 USD y tiene una capitalización bursátil de $247M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types…
| Periodo | 2026-11 | 2026-08 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.59 | $-0.49 | $-0.37 |
| Estimado | $-0.55 | $-0.48 | $-0.61 | $-0.48 |
| Sorpresa | — | -22.9% | +19.7% | +22.9% |
| Métrica | ZNTL | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -63.4% | -40.4% | -23.0% |
| ROA | -47.4% | -32.0% | -15.4% |
| Current Ratio | 6.93 | 2.84 | +4.09 |
| Debt / Equity | — | 0.28 | — |